The Indian pharmaceutical sector witnessed a major infusion of capital on Tuesday, with Singapore-based private equity platform Everstone Capital announcing a substantial investment in the Gujarat-based Apothecon Group. The funding round, valued at USD 270 million (approximately Rs 2,510 crore), targets both Apothecon and its US sister concern, Navinta.
The investment aims to secure a substantial stake, marking a vote of confidence in the group's diversified and rapidly growing pharmaceutical portfolio. Apothecon Group, established in 2003, specializes in critical dosage forms, including injectables and oral solids.
Capital Infusion Targets Growth and US Expansion
Everstone Capital's strategic focus will be multi-pronged, aiming to accelerate and augment the company's product pipeline. The investment is structured not only for growth but also for expanding the commercial footprint across new international geographies.A key part of the plan involves pursuing complementary acquisitions to build the company's scale. Mahendra Patel, the founding promoter, confirmed that the funding will be crucial for expanding the manufacturing footprint and significantly accelerating research and development efforts.
Global Manufacturing Prowess and Business Model Resilience
Apothecon Group boasts robust capabilities across complex chemistry areas. Its operational backbone includes a regulated markets-compliant manufacturing and R&D platform.The company maintains facilities across multiple jurisdictions, including Vadodara and Hyderabad in India, and key locations in New Jersey and Florida in the US. Atul Kapur, co-founder and chief investment officer of Everstone Group, highlighted the group's strength.
Kapur noted that Apothecon operates a resilient and self-reliant business model, successfully serving markets in the US, Europe, and beyond through its own established manufacturing facilities.
Governance and Strategic Leadership Streamline
To ensure continuity and strategic oversight, the founding promoters will retain a meaningful stake in the company. While Mahendra Patel continues as the chairman, the PE investor has appointed Puncham Mukim and Arjun Oberoi as nominees to the board.According to Everstone Group's co-founder, the belief is that this partnership will help the company reach new operational heights. Kapur expressed optimism, stating, "We expect the company to reach greater heights and look forward to the next chapter together."
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.